Author

J. Skidmore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:host-pathogen & immune response· 1 Approach:machine learning (classical)· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

A. R. Venkitaraman· 2 shared C. Abell· 2 shared D. E. Scott· 2 shared G. Fischer· 2 shared G. McKenzie· 2 shared R. Srinivasan· 2 shared T. L. Blundell· 2 shared T. Moschetti· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. R. Venkitaraman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antibody-dependent Intracellular neutralisation by TRIM21 is potentiated by HOIP and linear ubiquitin chains

C. S. Green, K. F. Winklhofer, A. J. Fletcher, L. C. James, J. Skidmore, J. Duce, W. A. McEwan

This study identifies HOIP and linear ubiquitin chains as critical for TRIM21-mediated ADIN by recruiting VCP, enhancing virus neutralization.

bioRxiv · Apr 2, 2024 · PreprintImmunology

LeGenD: determining N-glycoprofiles using an explainable AI-leveraged model with lectin profiling

H. Li, A. G. Peralta, S. Schoffelen, A. H. Hansen, J. Arnsdorf, S.-M. Schinn, J. Skidmore, B. Choudhury, M. Paulchakrabarti, B. G. Voldborg, A. W. T. Chiang, N. E. Lewis

LeGenD predicts N-glycan structures and their abundance using lectin-binding patterns and AI, trained on glycoprofiles from recombinant proteins.

bioRxiv · Mar 27, 2024 · PreprintBioengineering

Selective inhibitors of the Aurora A-TPX2 protein-protein interaction exhibit in vivo efficacy as targeted anti-mitotic agents

S. R. Stockwell, D. E. Scott, G. Fischer, E. Guarino, T. P. C. Rooney, T.-S. Fang, T. Moschetti, R. Srinivasan, E. Alza, A. Asteian, C. Dagostin, A. Alcaide, M. Rocaboy, B. Blaszczyk, A. Higueruelo, , M. Hyvönen

The paper develops selective Aurora A-TPX2 inhibitors that show in vivo efficacy and synergy with paclitaxel in pancreatic cancer.

bioRxiv · Mar 22, 2023 · PreprintBiochemistry

A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death

D. E. Scott, N. J. Francis-Newton, M. E. Marsh, A. G. Coyne, G. Fischer, T. Moschetti, A. R. Bayly, T. D. Sharpe, K. T. Haas, L. Barber, C. Valenzano, R. Srinivasan, D. J. Huggins, M. Ehebauer, A. Esposito, , C. Abell

The paper identifies CAM833, a small-molecule inhibitor of BRCA2-RAD51 interaction, which disrupts RAD51 assembly and enhances DNA damage-induced cell death in BRCA2-wildtype cells.

bioRxiv · Jul 15, 2020Cancer Biology